The leading representative office of defined Corporate Investor is situated in the Shanghai. The venture was found in Asia in China.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Ample Harvest Finance, startups are often financed by YF Capital (Yunfeng Capital), Lang Sheng Investment. The meaningful sponsors for the fund in investment in the same round are V-Capital, ShenZhen GTJA Investment Group, China Weibo Developer Innovation Fund. In the next rounds fund is usually obtained by Harvest Global Investments.
The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2017.
Among the most popular fund investment industries, there are Biotechnology, Pharmaceutical. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Viroad Biotechnology For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
Related Funds
Fund Name | Location |
Ally Corporate Finance | - |
Almaworks | New City, New York, United States |
Culture Convenience Club (CCC) | Japan, Tokyo |
EquipmentShare | Columbia, Missouri, United States |
Fink Family Foundation | - |
Frind Holdings | - |
Hua Hsia Investment Holding Co | Taipei, Taiwan |
IBB Beteiligungsgesellschaft | Berlin, Berlin, Germany |
IESE Business School | Barcelona, Catalonia, Spain |
JiangSu QianRong Assets Management | China, Jiangsu, Suzhou |
Odey Asset Management | England, London, United Kingdom |
OneSpan | Chicago, Illinois, United States |
Pathway Bioventures | Chicago, Illinois, United States |
Suzhou Ventures | China, Jiangsu, Suzhou |
u2i | - |
Vertex Ventures US | California, Palo Alto, United States |
WJWcoin | - |
Xinghan Capital | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
SPH Health Commerce | $154M | 18 Feb 2021 | Xuhui, Shanghai, China | ||
Yao123.com | $46M | 27 Apr 2019 | Shanghai, China | ||
$46M | 26 Apr 2019 | China, Shanghai | |||
Viroad Biotechnology | $4M | 20 Apr 2017 | Shijiazhuang City, Hebei | ||
Lens Magazine | $463K | 21 Feb 2017 | Dongcheng District, Beijing, China | ||
$1M | 23 Mar 2016 | Changning District, China | |||
$463K | 26 Jun 2015 | Changning District, China | |||
$463K | 02 Jun 2015 | Shanghai, China | |||
Ling Yi Caijing | $463K | 07 May 2015 | China, Beijing |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
SPH Health Commerce | $154M | 18 Feb 2021 | Xuhui, Shanghai, China | ||
Yao123.com | $46M | 27 Apr 2019 | Shanghai, China | ||
$46M | 26 Apr 2019 | China, Shanghai | |||
Viroad Biotechnology | $4M | 20 Apr 2017 | Shijiazhuang City, Hebei | ||
Lens Magazine | $463K | 21 Feb 2017 | Dongcheng District, Beijing, China | ||
$1M | 23 Mar 2016 | Changning District, China | |||
$463K | 26 Jun 2015 | Changning District, China | |||
$463K | 02 Jun 2015 | Shanghai, China | |||
Ling Yi Caijing | $463K | 07 May 2015 | China, Beijing |